Monetary Policy and Economic Outlook - The People's Bank of China released the monetary policy execution report for Q3 2025, indicating that the domestic economic recovery needs further consolidation. The central bank plans to deepen financial reforms and enhance high-level opening-up, aiming to build a robust monetary policy system and a comprehensive macro-prudential management framework [1][2]. Manufacturing and Infrastructure Development - The Ministry of Industry and Information Technology issued a notice to accelerate the systematic layout and high-level construction of manufacturing pilot platforms, targeting the establishment of a modern pilot platform system by the end of 2027 [1][3]. - The National Development and Reform Commission announced that the infrastructure real estate investment trusts (REITs) will enter a normalized issuance phase in 2024, with 105 projects recommended to the China Securities Regulatory Commission, totaling 207 billion yuan in funds, expected to drive over 1 trillion yuan in new project investments [3]. New Energy Vehicle Industry - The Chinese automotive industry reported record growth in the new energy vehicle sector, with October 2025 seeing monthly new car sales of new energy vehicles surpassing 50% of total new car sales for the first time [1][3]. Chemical Industry Insights - Seven chemical-themed funds have been reported since Q3, with a focus on the chemical sector's supply-side changes, including stricter approvals for new capacities. The industry is expected to see a recovery in profitability and valuation [11]. Battery and Renewable Energy Sector - The 12th China (Suzhou) Battery New Energy Industry International Summit highlighted China's competitive advantage in the lithium battery sector, with over 90% of global shipments in energy storage lithium batteries. Future demand for lithium batteries is expected to grow, particularly in energy storage applications [7]. Pharmaceutical Logistics Development - Shanghai's new guidelines aim to enhance the development of modern pharmaceutical logistics, promoting the establishment of a high-efficiency and professional logistics system to ensure drug supply and quality [6].

Company Announcements - *ST Zhengping has completed the stock suspension review and will resume trading on November 12, confirming normal production and operation without significant changes [1] - Upwind New Materials is in the product development stage for its embodied intelligent robot business, which has not yet achieved mass production or revenue generation [2] - Shannon Chip Innovation's fourth largest shareholder, Shenzhen Xinlianpu, has pledged 1.27 million shares for financing purposes [3] - Qing Shui Yuan's phosphorus trichloride products are primarily used in the production of water treatment agents [4] - Midea Group announced a cash dividend plan of 5 yuan per 10 shares, totaling 3.448 billion yuan, with the record date on November 17 [4] - Huiyuan Communication is planning a change of control, leading to a stock suspension starting November 12 [5] - Shen Gong Co. has clarified that some research reports on its performance forecasts represent only analysts' personal views [6] - World is developing diamond micro-drills for PCB processing, which are still in the R&D phase [6] - Haike New Source has signed an agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent [7] - Tongxing Technology plans to invest 3.2 billion yuan in a project to produce 100,000 tons of sodium battery cathode materials and 6 GWh battery cells [8] Investments & Contracts - Zhongjin Irradiation is investing 200 million yuan to build an electronic accelerator intelligent manufacturing project [10] - Hongri Da is collaborating with Te Du Technology and Hongke Tongchuang to establish a joint venture for semiconductor packaging [10] Shareholding Changes - Jian Kai Technology's controlling shareholder Xuanzhao plans to transfer 3% of its shares through a pricing inquiry [12] - Yue Wannianqing's shareholder Hehe Investment intends to reduce its stake by up to 3% [14] Financing & Capital Increase - Weiteng Electric plans to raise up to 300 million yuan through a private placement for various manufacturing projects [22] Other Developments - Zhifei Biological has received approval for clinical trials of a vaccine for adolescents and adults [23] - Shanghai Kaibao has obtained approval for clinical trials of a drug for acute ischemic stroke [24]

（文章来源：证券日报） 证券日报网讯 11月11日晚间，博济医药发布公告称，近日，公司全资子公司广州博济新药临床研究中 心有限公司申报的"卿芷软膏"获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。 ...

北京商报讯(记者丁宁)11月11日晚间，博济医药（300404）发布公告称，公司全资子公司广州博济新药 临床研究中心有限公司申报的"卿芷软膏"获得国家药品监督管理局核准签发的《药物临床试验批准通知 书》。 公告显示，"卿芷软膏"为多味饮片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新 处方制剂，为1.1类中药创新药。本药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气 止痛。 ...

Group 1 - The core point of the article is that Boji Pharmaceutical's subsidiary has received approval for a clinical trial of a new drug, "Qingzhi Ointment," from the National Medical Products Administration [1] - As of January to June 2025, Boji Pharmaceutical's revenue composition shows that 99.46% comes from services, while other businesses account for 0.54% [1] - The current market capitalization of Boji Pharmaceutical is 3.9 billion yuan [1] Group 2 - The article also mentions that prior to the arrest of the chairman of Peking University Pharmaceutical, police had investigated the group's factory, indicating potential issues within the company [1] - Internal sources suggest that the group's assets have been disposed of by the chairman, with significant funds remaining unaccounted for [1]

格隆汇11月11日丨博济医药(300404.SZ)公布，全资子公司广州博济新药临床研究中心有限公司申报 的"卿芷软膏"获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。"卿芷软膏"为多味饮 片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新处方制剂，为1.1类中药创新 药。本药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。 ...

博济医药公告，全资子公司广州博济新药临床研究中心有限公司申报的"卿芷软膏"获得国家药品监督管 理局核准签发的《药物临床试验批准通知书》。"卿芷软膏"为多味饮片在中医药理论指导下组方而成的 制剂，属于未在境内外上市的中药新处方制剂，为1.1类中药创新药。本药品用于膝骨关节炎风寒湿痹 证，主治祛风胜湿，散寒通络，行气止痛。 ...

格隆汇11月11日｜博济医药(300404.SZ)公告称，公司全资子公司广州博济新药临床研究中心有限公司 申报的"卿芷软膏"获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。该药品为1.1类 中药创新药，用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。公司表示，这不会对 公司的经营业绩产生重大影响，后续将根据药品进展情况及时履行信息披露义务。但需注意药品研发周 期长、环节多，存在不确定性。 ...

"卿芷软膏"为多味饮片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新处方制剂， 为1.1类中药创新药。本药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。 博济医药（300404）(300404.SZ)发布公告，近日，公司全资子公司广州博济新药临床研究中心有限公 司申报的"卿芷软膏"获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。 ...

人民财讯11月11日电，博济医药（300404）11月11日公告，公司全资子公司广州博济新药临床研究中心 有限公司申报的"卿芷软膏"获得国家药监局核准签发的《药物临床试验批准通知书》。"卿芷软膏"为多 味饮片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新处方制剂，为1.1类中药创 新药。该药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。 ...